MiniMed 670G automated insulin delivery system deemed safe for children 7 to 13 with type 1 diabetes

Steve, Joy, Kaytie, Kennon and Michelle are all back from the ADA 78th Scientific sessions. This turned out to be a great year to have our largest reporting staff ever. There were so many things to cover that I almost wish I had not been cycling in the hills of …

New mobile app from Medtronic, Sugar.IQ™, applies AI technology from IBM Watson Health to help people with diabetes make more informed decisions.

With over 6 million possible combinations, it is difficult to come up with the best treatment for each patient. The phase III DURATION-8 trial may help you to decide.

DEPICT-2 study of more than 800 people worldwide indicates positive results without added risk of severe hypoglycemia, but slight increase in DKA events.

One-year results of North American inTandem1 study show decreased HbA1c levels and lower risk of severe hypoglycemia.

The FDA approved the 90-day version of the implantable CGM Sensor.

For those who use insulin, accuracy is one of the most important things to consider when using a CGM.

“Simple,” “Accurate,” and “Effective” were the words ADA presenters used to describe Dexcom G6, a new continuous glucose monitor (CGM) system.

A dual-hormone, artificial pancreas delivering rapid insulin and the drug pramlintide improved glucose management and reduced glucose variability in adults with type 1 compared to an insulin-only, first-generation artificial pancreas.